Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
Fuji
Moodys
Express Scripts
Queensland Health
UBS
Dow
Harvard Business School

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,018,992

« Back to Dashboard

Which drugs does patent 7,018,992 protect, and when does it expire?

Patent 7,018,992 protects VAGIFEM and is included in one NDA.

This patent has eleven patent family members in ten countries.
Summary for Patent: 7,018,992
Title:Hormone composition
Abstract:Twice weekly administration of an analog to a Vagifem tablet which only contains 10 .mu.g of active material has a sufficient effect.
Inventor(s): Koch; Karen (Charlottenlund, DK), Kvorning; Ingelise (Bronshoj, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:10/016,858
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,018,992

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novo Nordisk Inc VAGIFEM estradiol TABLET;VAGINAL 020908-002 Nov 25, 2009 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,018,992

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2000 01891Dec 15, 2000
Denmark2000 01892Dec 15, 2000
Denmark2000 01890Dec 15, 2000

International Patents Family Members for US Patent 7,018,992

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2010189409 ➤ Try a Free Trial
Japan 4851057 ➤ Try a Free Trial
Japan 2004515531 ➤ Try a Free Trial
Spain 2376649 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
McKesson
Moodys
Merck
Baxter
Harvard Business School
US Department of Justice
Cipla
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.